The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | How may purinostat methylate fit into the current treatment landscape for R/R MM and DLBCL?
Lijuan Chen, MD, PhD, West China Hospital, Sichuan University, Chengdu, China, comments on the potential role of purinostat methylate (PM) in the current treatment landscape of relapsed/refractory multiple myeloma (R/R MM) and diffuse large B-cell lymphoma (DLBCL), highlighting their ability to bridge the gap between diagnosis and CAR T-cell therapy, and to mitigate treatment related side effects. Dr Chen notes that while CAR T-cell therapy is a valuable treatment option, its high cost, limited accessibility, and potential for severe side effects create a need for alternative or complementary therapies. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
